Redwood AI Collaborates with Resilience Biosciences on AI-Driven Drug Development

Redwood AI Corp. has announced a collaboration with Resilience Biosciences Inc. to develop AI-assisted workflows for small-molecule drug discovery. This partnership allows Resilience to leverage Redwood's AI platform, streamlining the search for drug-like molecules by efficiently exploring new chemical designs.

The focus of their collaboration includes computational chemistry, cheminformatics, and synthetic route design, aligning with Resilience’s goals in small-molecule development. The collaboration aims to enhance systematic derivative generation, patentability assessments, and retrosynthetic analysis for potential drugs.

Redwood will support Resilience with a synthetic assistance workflow to modify drug scaffolds and discover novel chemical spaces. The aim is to enhance early-stage scientific analysis through in-silico synthesis planning and expert chemist reviews.

Resilience is focused on non-opioid therapeutics for withdrawal-related pain and symptoms. Their partnership with Redwood aligns with their strategy to strengthen their portfolio in addiction and pain therapies.